1
|
Filgueira LM, Cervantes JB, Lovelle OA, Herrera C, Figueredo C, Caballero JA, Sánchez N, Berrio J, Lorenzo G, Cepeda M, Ramos M, Saavedra D, Añe-Kouri AL, Mazorra Z, Leon K, Crombet T, Caballero A. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases. Immunotherapy 2021; 13:289-295. [PMID: 33397150 PMCID: PMC7784786 DOI: 10.2217/imt-2020-0235] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. Itolizumab is a monoclonal antibody that recognizes human CD6 expressed in activated T cells. The antibody has shown to be safe and efficacious in the treatment of moderate to severe psoriasis. Its effect is associated with the reduction of pro-inflammatory cytokines release, including IFN-γ, IL-6 and TNF-α. Here, we report the outcome of three severe and critically ill COVID-19 patients treated with itolizumab as part of an expanded access protocol. Itolizumab was able to reduce IL-6 concentrations in all the patients. Two of the three patients showed respiratory and radiological improvement and were fully recovered. We hypothesize this anti-inflammatory therapy in addition to antiviral and anticoagulant therapy could reduce COVID-19 associated morbidity and mortality.
Collapse
Affiliation(s)
- Lázaro Manuel Filgueira
- Manuel Piti Fajardo University Hospital, Ciudad Escolar Abel Santamaría. U/M 9958, Santa Clara city, Villa Clara, Cuba
| | - Julio Betancourt Cervantes
- Manuel Piti Fajardo University Hospital, Ciudad Escolar Abel Santamaría. U/M 9958, Santa Clara city, Villa Clara, Cuba
| | - Orlando Adolfo Lovelle
- Manuel Piti Fajardo University Hospital, Ciudad Escolar Abel Santamaría. U/M 9958, Santa Clara city, Villa Clara, Cuba
| | - Carlos Herrera
- Arnaldo Milián University Hospital, Santa Clara St., Santa Clara city, Villa Clara, Cuba
| | - Carlos Figueredo
- Manuel Piti Fajardo University Hospital, Ciudad Escolar Abel Santamaría. U/M 9958, Santa Clara city, Villa Clara, Cuba
| | - Jorge Alain Caballero
- Arnaldo Milián University Hospital, Santa Clara St., Santa Clara city, Villa Clara, Cuba
| | - Naivy Sánchez
- Manuel Piti Fajardo University Hospital, Ciudad Escolar Abel Santamaría. U/M 9958, Santa Clara city, Villa Clara, Cuba
| | - Jorge Berrio
- Manuel Piti Fajardo University Hospital, Ciudad Escolar Abel Santamaría. U/M 9958, Santa Clara city, Villa Clara, Cuba
| | - Geidy Lorenzo
- Center of Molecular Immunology, 216 St, corner 15, Atabey, Havana, Cuba
| | - Meylan Cepeda
- Center of Molecular Immunology, 216 St, corner 15, Atabey, Havana, Cuba
| | - Mayra Ramos
- Center of Molecular Immunology, 216 St, corner 15, Atabey, Havana, Cuba
| | - Danay Saavedra
- Center of Molecular Immunology, 216 St, corner 15, Atabey, Havana, Cuba
| | - Ana Laura Añe-Kouri
- Superior Institute of Basic & Preclinical Sciences of Havana "Victoria de Girón", Street 25, Playa, Havana, Cuba
| | - Zaima Mazorra
- Center of Molecular Immunology, 216 St, corner 15, Atabey, Havana, Cuba
| | - Kalet Leon
- Center of Molecular Immunology, 216 St, corner 15, Atabey, Havana, Cuba
| | - Tania Crombet
- Center of Molecular Immunology, 216 St, corner 15, Atabey, Havana, Cuba
| | - Armando Caballero
- Arnaldo Milián University Hospital, Santa Clara St., Santa Clara city, Villa Clara, Cuba
| |
Collapse
|